Trial Profile

A phase 1/2 multiple ascending dose (MAD) trial of ENTR-601-45 in patients with Duchenne muscular dystrophy (DMD) who are exon 45 skipping amenable

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Mar 2025 According to an Entrada Therapeutics media release, the company has received authorization in the United Kingdom to initiate this phase 1/2 study, which is on track to be initiated in Q3 2025. The company plans to initiate and run the studies in the U.K. and EU and then share these study results with the FDA to potentially enable registrational studies in the U.S. Regulatory filings have been submitted to EU and review is ongoing.
13 May 2024 New trial record
07 May 2024 According to an Entrada Therapeutics media release, company is on track to submit regulatory applications in the fourth quarter of 2024 to initiate independent global Phase 2 clinical development study for ENTR-601-45 in patients with DMD who are exon 45 skipping amenable.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com